Melanie B. Thomas, MD, discusses the rationale of a phase II study of adjuvant capecitabine/gemcitabine for extrahepatic cholangiocarcinoma and gallbladder carcinoma.
Melanie B. Thomas, MD
Advertisement
Articles by Melanie B. Thomas, MD
Melanie B. Thomas, MD, discusses the potential utility for the monoclonal antibody PF-03446962 in hepatocellular carcinoma (HCC).
Advertisement
Latest Updated Articles
The Monoclonal Antibody PF-03446962 for HCCPublished: June 16th 2014 | Updated:
Adjuvant Capecitabine/Gemcitabine for EHCC and GBCAPublished: September 12th 2014 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5
